News - Page 141 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Post published:November 16, 2021
Post category:Press Release

Read more about the article MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

Post published:November 16, 2021
Post category:Press Release

Read more about the article MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

Post published:November 15, 2021
Post category:Press Release

Read more about the article atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

Post published:November 15, 2021
Post category:Press Release

Read more about the article Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Post published:November 15, 2021
Post category:Press Release

Read more about the article Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Post published:November 15, 2021
Post category:Press Release

Read more about the article Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

Post published:November 15, 2021
Post category:Press Release

Read more about the article Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory

Post published:November 15, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Post published:November 15, 2021
Post category:Psychedelic Bulletin

Read more about the article PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Post published:November 11, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.